The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...
"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...
Medpage Today on MSN6d
Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune ThrombocytopeniaSAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet ...
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...
Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...
BTIG initiated coverage of Nurix Therapeutics (NRIX) with a Buy rating and $35 price target Nurix is a protein degrader company whose lead ...
Rilzabrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).
New Delhi: Pharmaceutical major Glenmark Pharmaceuticals has got the go-ahead from the Subject Expert Committee (SEC) ...
Eli Lilly (LLY) and Company announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent Bruton’s tyrosine ...
Tolebrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Secondary Progressive Multiple Sclerosis (SPMS).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback